Stocks
Amgen's Earnings Hit by Novartis Pelacarsen Miss: UBS
UBS analysts have expressed disappointment in Amgen's (AMGN) latest earnings, specifically citing Novartis' pelacarsen miss as a concern for the company's performance.
The analysts stated that this particular miss is 'not great on the margin' for Amgen, implying that it has had an impact on their expectations for the company's future results.
No further details were provided in the statement from UBS about how they expect Amgen to recover or what specific changes they anticipate the company will make as a result of this miss.